Repligen (NASDAQ:RGEN) Stock Rating Lowered by Benchmark

Benchmark lowered shares of Repligen (NASDAQ:RGEN – Free Report) from a buy rating to a hold rating in a research note published on Monday morning, MarketBeat reports. Other equities analysts have also issued reports about the stock. Royal Bank of Canada decreased their target price on shares of Repligen from $207.00 to $200.00 and set […]

Leave a Reply

Your email address will not be published.

Previous post Pfizer (NYSE:PFE) Given “Buy” Rating at Truist Financial
Next post Qualys (NASDAQ:QLYS) Rating Lowered to Hold at StockNews.com